| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1001773070 |
| P356 | DOI | 10.1038/BMT.2013.190 |
| P698 | PubMed publication ID | 24292521 |
| P50 | author | José Luis López-Hontangas | Q86100712 |
| P2093 | author name string | G Martín | |
| M A Sanz | |||
| C Salazar | |||
| I Jarque | |||
| J Sanz | |||
| A Sempere | |||
| M Salavert | |||
| I Lorenzo | |||
| F Moscardó | |||
| E Mayordomo | |||
| G F Sanz | |||
| L Senent | |||
| M Arango | |||
| P Montesinos | |||
| B Boluda | |||
| C Cañigral | |||
| P2860 | cites work | Estimation of failure probabilities in the presence of competing risks: new representations of old estimators | Q33594562 |
| Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients | Q33634455 | ||
| Donor-derived second hematologic malignancies after cord blood transplantation | Q33952705 | ||
| Successful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes. | Q34450754 | ||
| Persistence of the Epstein-Barr virus and the origins of associated lymphomas | Q35715171 | ||
| Posttransplant lymphoproliferative disorder: significance of central nervous system involvement | Q36105111 | ||
| Infectious complications following unrelated cord blood transplantation | Q36800530 | ||
| Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation | Q37201899 | ||
| Impact of hematopoietic chimerism at day +14 on engraftment after unrelated donor umbilical cord blood transplantation for hematologic malignancies | Q37207777 | ||
| How I treat EBV lymphoproliferation | Q37414678 | ||
| Human immunodeficiency virus (HIV)-negative plasmablastic lymphoma: a single institutional experience and literature review | Q37900725 | ||
| Post transplant lymphoproliferative disorders: risk, classification, and therapeutic recommendations. | Q37975458 | ||
| Increased incidence of EBV-related disease following paediatric stem cell transplantation with reduced-intensity conditioning | Q40511369 | ||
| Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation | Q42154867 | ||
| Clinicopathologic spectrum and EBV status of post-transplant lymphoproliferative disorders after allogeneic hematopoietic stem cell transplantation | Q42282037 | ||
| Cord blood transplantation from unrelated donors in adults with high-risk acute myeloid leukemia. | Q43278450 | ||
| Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia | Q43547992 | ||
| Incidence, risk factors, and outcome of cytomegalovirus infection and disease in patients receiving prophylaxis with oral valganciclovir or intravenous ganciclovir after umbilical cord blood transplantation | Q45123479 | ||
| Plasma Epstein-Barr virus (EBV) DNA is a biomarker for EBV-positive Hodgkin's lymphoma. | Q45420586 | ||
| Fatal central nervous system lesions emerging during anti-CD20 monoclonal antibody therapy (Rituximab) for a post transplantation Epstein Barr virus-linked lymphoma | Q45726927 | ||
| Allogeneic haematopoietic stem-cell transplantation with reduced intensity conditioning for advanced stage Hodgkin's lymphoma in Sweden: high incidence of post transplant lymphoproliferative disorder | Q46734531 | ||
| A Proportional Hazards Model for the Subdistribution of a Competing Risk | Q56885139 | ||
| Lymphoproliferative disorders following allogeneic bone marrow transplantation: the Vancouver experience | Q57649423 | ||
| Single-unit umbilical cord blood transplantation from unrelated donors in patients with hematological malignancy using busulfan, thiotepa, fludarabine and ATG as myeloablative conditioning regimen | Q58865842 | ||
| Central nervous system lymphomas in organ allograft recipients | Q72487023 | ||
| Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study | Q73023273 | ||
| Incidence and risk factors of EBV reactivation after unrelated cord blood transplantation: a Eurocord and Société Française de Greffe de Moelle-Therapie Cellulaire collaborative study | Q84543267 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | post-transplant lymphoproliferative disorder | Q1594599 |
| P304 | page(s) | 397-402 | |
| P577 | publication date | 2013-12-02 | |
| P1433 | published in | Bone Marrow Transplantation | Q4941523 |
| P1476 | title | EBV-associated post-transplant lymphoproliferative disorder after umbilical cord blood transplantation in adults with hematological diseases | |
| P478 | volume | 49 |
| Q41281408 | Cellular immunotherapy with ex vivo expanded cord blood T cells in a humanized mouse model of EBV-associated lymphoproliferative disease. |
| Q64061449 | Central nervous system infections in immunocompromised patients |
| Q89551910 | Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disorders after Hematopoietic Stem Cell Transplantation: Pathogenesis, Risk Factors and Clinical Outcomes |
| Q26861623 | Epstein-Barr virus lymphoproliferative disease after hematopoietic stem cell transplant |
| Q89748152 | Epstein-Barr virus reactivation after allogeneic hematopoietic stem cell transplantation: multifactorial impact on transplant outcomes |
| Q33766984 | From patient centered risk factors to comprehensive prognostic models: a suggested framework for outcome prediction in umbilical cord blood transplantation |
| Q62787914 | Haploidentical transplantation is associated with better overall survival when compared to single cord blood transplantation: an EBMT-Eurocord study of acute leukemia patients conditioned with thiotepa, busulfan, and fludarabine |
| Q40590036 | Herpesvirus Respiratory Infections in Immunocompromised Patients: Epidemiology, Management, and Outcomes. |
| Q34802425 | High day 28 ST2 levels predict for acute graft-versus-host disease and transplant-related mortality after cord blood transplantation |
| Q38848582 | Infection Rates among Acute Leukemia Patients Receiving Alternative Donor Hematopoietic Cell Transplantation |
| Q28066500 | Infectious Complications after Umbilical Cord-Blood Transplantation from Unrelated Donors |
| Q26745838 | Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines |
| Q96304945 | Management of Epstein-Barr virus-related post-transplant lymphoproliferative disorder after allogeneic hematopoietic stem cell transplantation |
| Q88802166 | Management of Non-Diffuse Large B Cell Lymphoma Post-Transplant Lymphoproliferative Disorder |
| Q89217688 | Post-transplant lymphoproliferative disorders |
| Q90340384 | Pre-emptive rituximab treatment for Epstein-Barr virus reactivation after allogeneic hematopoietic stem cell transplantation is a worthwhile strategy in high-risk recipients: a comparative study for immune recovery and clinical outcomes |
| Q47587300 | Risk factors for post-transplant lymphoproliferative disorder after Thymoglobulin-conditioned hematopoietic cell transplantation. |
| Q36009655 | Screening and Monitoring for Infectious Complications When Immunosuppressive Agents Are Studied in the Treatment of Autoimmune Disorders |
| Q50104242 | Second Malignancies after Hematopoietic Stem Cell Transplantation |
| Q41353081 | Umbilical cord blood transplantation in adults with advanced hodgkin's disease: high incidence of post-transplant lymphoproliferative disease |
| Q64061464 | Update in Infectious Diseases 2018 |
| Q54326551 | [Advances on Epstein-Barr virus related post-transplant lymphoproliferative disorders after allogeneic hematopoietic stem cell transplantation]. |
Search more.